A key House Republican wants to make changes to a Senate-passed measure that aims to expand patient access to experimental treatments, a move that will slow the measure’s path to passage.
House Energy and Commerce Committee Chairman Greg Walden of Oregon told STAT Thursday that the Senate-passed “right-to-try” bill, from Sen. Ron Johnson (R-Wis.), would have to be changed before he would bring it up in his panel.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
